Oppenheimer initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $7 price target The firm said the rating is based on its conviction for lead asset OV329 to address epilepsy disorders with validating clinical data. OV329 modulates GABA to calm seizures, and Oppenheimer sees a $1B+ potential market opportunity, the firm tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID: